HeartWare International Inc  

(Public, NASDAQ:HTWR)   Watch this stock  
Find more results for HTWR
88.91
+0.39 (0.44%)
Mar 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 87.80 - 90.16
52 week 69.05 - 97.60
Open 88.30
Vol / Avg. 136,747.00/165,816.00
Mkt cap 1.53B
P/E     -
Div/yield     -
EPS -1.15
Shares 17.24M
Beta -0.06
Inst. own 106%
Apr 29, 2015
Q1 2015 HeartWare International Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Mar 10, 2015
HeartWare International Inc at Barclays Healthcare Conference - Webcast
Mar 3, 2015
HeartWare International Inc at Raymond James Institutional Investors Conference - Webcast
Feb 26, 2015
Q4 2014 HeartWare International Inc Earnings Release
Feb 26, 2015
Q4 2014 HeartWare International Inc Earnings Call - Webcast
Feb 12, 2015
HeartWare International Inc at Leerink Global Healthcare Conference
Feb 4, 2015
HeartWare International Inc at FIG Partners West Coast CEO Forum
Jan 13, 2015
HeartWare International Inc at JPMorgan Healthcare Conference Q&A session
Jan 13, 2015
HeartWare International Inc at JPMorgan Healthcare Conference - Webcast
Jan 13, 2015
Preliminary Q4 2014 HeartWare International Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -1.25% -6.96%
Operating margin 5.57% -0.04%
EBITD margin - -5.37%
Return on average assets -0.86% -4.54%
Return on average equity -1.78% -9.51%
Employees 585 -
CDP Score - -

Address

500 Old Connecticut Path
FRAMINGHAM, MA 1701
United States - Map
+1-508-7390873 (Phone)
+1-508-7390948 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Heartware International, Inc. (HeartWare) develops and manufactures small implantable heart pumps or ventricular assist devices to treat patients suffering from advanced heart failure. The HeartWare Ventricular Assist System (the HVAD System), which includes a ventricular assist device (VAD), or blood pump, patient accessories and surgical tools, is designed to provide circulatory support for patients in the advanced stage of heart failure. The core of the HVAD System is a continuous flow blood pump, the HVAD Pump, which is a full-output device capable of pumping up to 10 liters of blood per minute. The HVAD System is designed to be implanted adjacent to the heart, avoiding the abdominal surgery generally required to implant similar devices.

Officers and directors

C. Raymond Larkin Jr. Independent Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Douglas Evan Godshall M.B.A. President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Seth L. Harrison M.D. Deputy Chairman of the Board
Age: 54
Bio & Compensation  - Reuters
Peter F. McAree Chief Financial Officer, Senior Vice President, Treasurer
Age: 50
Bio & Compensation  - Reuters
Jeffrey A. LaRose Executive Vice President, Chief Scientific Officer
Age: 52
Bio & Compensation  - Reuters
Lawrence Knopf Senior Vice President, General Counsel, Company Secretary
Age: 53
Bio & Compensation  - Reuters
James Schuermann Senior Vice President - Sales and Marketing
Age: 46
Bio & Compensation  - Reuters
Mark Strong Senior Vice President, Research and Development and Quality
Age: 43
Bio & Compensation  - Reuters
Robert Yocher Senior Vice President, Regulatory Affairs
Age: 63
Bio & Compensation  - Reuters
Katrin Leadley M.D. Chief Medical Officer
Age: 52
Bio & Compensation  - Reuters